Objective assessment of acne

Becker, Markus; Wild, T. Cameron; Zouboulis, Christos C.

doi:10.1016/j.clindermatol.2016.10.006

Cited by 26 publications

(30 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acne severity was rated by clinical evaluation using: 1) the Global Acne Grading System (GAGS) score consisting in a subjective assessment of acne severity proposed by Doshi et al in 1997 that divides the face into six areas, forehead, nose, chin, right cheek, left cheek, chest and upper back and assigns a factor (from 1 to 3) to each area (2=forehead; 1=nose; 1=chin; 2= right cheek; 2= left cheek; 3=chest and upper back): the local score is calculated using the formula factor x grade (depending on the most severe lesion type; 0= no lesions; 1= comedones; 2=papules; 3=pustules; 4=nodules); the global score is the sum of all global scores: a score of 1-18 is considered mild; 19-30 moderate; 31-38 severe and >39 very severe and by 2) lesions count, method based on count of the total number of retentional and/or inflammatory lesions. 12,13 Instrumental assessment included: 1) measurement of sebum by Sebutape TM strips (CuDerm Corp., Dallas, TX, USA) placed on the patient's forehead, nose, cheeks, and chin and subsequently checked against a black background of a score card; sebum spots are scored on a scale ranging from 1 to 5, where 1 indicates a dry skin without sebum, and 5 identifies a very oily skin, and 2) facial imaging performed by high-tech facial photography characterized by 15 mega pixel resolution and flash cross-polarized Light by Reveal Photo Imager (Canfield Scientific Inc., Parsippany, NJ, USA) at Naples site and by VISIA-CR™ imaging system (Canfield Scientific Inc., Fairfield, NJ, USA) at Catania site. [14][15][16] Additionally, evaluation of product tolerability by a self-administered questionnaire based on 5 parameters (erythema, scaling, dryness, stinging/burning and itch) from 0 to 3 (0 =none; 1=mild; 2=moderate; 3=severe) was carried out.…”

Section: Clinical and Instrumental Evaluation Criteriamentioning

confidence: 99%

<p>Licochalcone A in Combination with Salicylic Acid as Fluid Based and Hydroxy-Complex 10% Cream for the Treatment of Mild Acne: A Multicenter Prospective Trial</p>

Dall’Oglio¹,

Fabbrocini²,

Tedeschi³

et al. 2020

CCID

View full text Add to dashboard Cite

Purpose: Topical cosmetic agents if correctly prescribed and used may improve outcomes in acne therapy. The aim of this study was to assess the efficacy and tolerability of a new daily cosmetic regimen in the treatment of mild facial acne. Patients and methods: A multicenter, prospective, observational, clinical study was conducted on 91 adult patients with mild acne. Subjects were instructed to apply a fluid containing Licochalcone A/Salicylic acid/L-Carnitine in the morning and a cream with Licochalcone A/Hydroxy-Complex 10% at bedtime for 8 weeks. The efficacy was clinically evaluated by Global Acne Grading System (GAGS) score and by comedones/papules lesions count and by instrumental assessment (Sebutape TM and Reveal Photo Imager/VISIA-CR™ imaging) at baseline, at 4 and 8 weeks. Results: At 4 weeks a statistically significant reduction from baseline of GAGSwas observed. In addition, the mean total count of comedones and papules was significantly reduced by 41% and 45%, respectively, from baseline along with a significant reduction of mean sebum of 47%. At 8 weeks, a further statistically significant reduction from baseline of GAGS, total count of comedones and papules (64% and 71%, respectively), along with an additional sebum reduction of about 52% was also recorded. Conclusion: Our results suggest that the daily regimen based on Licochalcone A with Salicylic acid/L-Carnitine as fluid or with Hydroxy-Complex 10% as cream represent an interesting cosmetic approach for treating mild acne.

show abstract

Section: Clinical and Instrumental Evaluation Criteriamentioning

confidence: 99%

<p>Licochalcone A in Combination with Salicylic Acid as Fluid Based and Hydroxy-Complex 10% Cream for the Treatment of Mild Acne: A Multicenter Prospective Trial</p>

Dall’Oglio¹,

Fabbrocini²,

Tedeschi³

et al. 2020

CCID

View full text Add to dashboard Cite

show abstract

“…At present, there is a lack of standardized methods for evaluating treatment efficacy in acne, with at least 25 grading systems developed to date. [25][26][27][28] Current clinical evaluations include lesion counts, 29 global severity grading and comprehensive acne severity system (CASS) assessment, 30 which have limitations. For example, lesion counts are restricted by subjective evaluation, 31 and global severity grading cannot estimate the effect of treatment on individual lesions.…”

Section: Evaluation Of Treatment Efficacy: Giuseppe Micalimentioning

confidence: 99%

Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019

Luger

Dirschka

Eyerich

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

The 2019 Interactive Derma Academy (IDeA) meeting was held in Lisbon, Portugal, 10–12 May, bringing together leading dermatology experts from across Europe, the Middle East and Asia. Over three days, the latest developments and challenges in relation to the pathophysiology, diagnosis, evaluation and management of dermatological conditions were presented, with a particular focus on acne, atopic dermatitis (AD) and actinic keratosis (AK). Interesting clinical case studies relating to these key topics were discussed with attendees to establish current evidence‐based best practices. Presentations reviewed current treatments, potential therapeutic approaches and key considerations in the management of acne, AK and AD, and discussed the importance of the microbiome in these conditions, as well as the provision of patient education/support. It was highlighted that active treatment is not always required for AK, depending on patient preferences and clinical circumstances. In addition to presentations, two interactive workshops on the diagnosis and treatment of sexually transmitted infections/diseases (STIs/STDs) presenting to the dermatology clinic, and current and future dermocosmetics were conducted. The potential for misdiagnosis of STIs/STDs was discussed, with dermoscopy and/or reflectance confocal microscopy suggested as useful diagnostic techniques. In addition, botulinum toxin was introduced as a potential dermocosmetic, and the possibility of microbiome alteration in the treatment of dermatological conditions emphasized. Furthermore, several challenges in dermatology, including the use of lasers, the complexity of atopic dermatitis, wound care, use of biosimilars and application of non‐invasive techniques in skin cancer diagnosis were reviewed. In this supplement, we provide an overview of the presentations and discussions from the fourth successful IDeA meeting, summarizing the key insights shared by dermatologists from across the globe.

show abstract

“…Base line evaluation of the severity of acne was done by GAAS and lesional photography for each patient before the start of treatment with topical dapsone and tazarotene. Severe 4: inflammatory lesions more apparent,many papules ,pustules and may be few nodulocystic lesions.Very severe (5): highly inflammatory lesions and many nodulocystic lesions [10] . Patient`s response to treatment was recorded as, good, moderate and mild.Good response if: there was clearence of the comedones, papules and pustules >75%.…”

Section: Introductionmentioning

confidence: 99%

Effect of Dapsone Gel 7.5% Compared to Tazarotene Gel 0.1% for Treatment of Acne Vulgaris

Ibrahim¹,

Labeeb²,

Amer³

2019

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: Dapsone 7.5% gel was well tolerated, with a low incidence of treatment-related adverse events, with the majority of adverse events being related to topical application and mild or moderate in severity.Tazarotene helps to normalize the abnormal keratinization in the follicular infundibulum and changes the microenvironment of the follicle to reduce the proliferation of P. acnes. The aim of the study was to compare the efficacy and safety of dapsone gel 7.5% in relation to tazarotene gel 0.1% in the treatment of acne vulgaris. Methods: This study included 38 patients with different grades of AV, of different sexes and their ages ≥ 12 years, the patients were randomly selected from the outpatients clinics. Provided that the patients had not received any topical or systemic treatment for AV during the previous 2 weeks. A base line evaluation of the severity of acne was done by GAAS and lesional photography for each patient before the start of treatment with topical dapsone and tazarotene,then follow up at 2,4,8,12 weeks of treatment. Results: There is statistically significant difference between dapsone and tazarotene in side effects after treatment as 71.1% of the studied patients didn't complain of any side effects after dapsone while only 18.4 % of the studied patients had no side effects after tazarotene. The response to treatment with dapsone on the right side and tazarotene on the left side among the studied acne patients showed mild improvement occured in 28.9% after dapsone and occured in 15.8 % after tazarotene treatment, with no significant difference between both drugs. Conclusions: Dapsone 7.5% gel is a successful, effective and safe alternative in the treatment of acne vulgaris with insignificant side effects.

show abstract

Objective assessment of acne

Cited by 26 publications

References 45 publications

<p>Licochalcone A in Combination with Salicylic Acid as Fluid Based and Hydroxy-Complex 10% Cream for the Treatment of Mild Acne: A Multicenter Prospective Trial</p>

<p>Licochalcone A in Combination with Salicylic Acid as Fluid Based and Hydroxy-Complex 10% Cream for the Treatment of Mild Acne: A Multicenter Prospective Trial</p>

Developments and challenges in dermatology: an update from the Interactive Derma Academy (IDeA) 2019

Effect of Dapsone Gel 7.5% Compared to Tazarotene Gel 0.1% for Treatment of Acne Vulgaris

Contact Info

Product

Resources

About